There Are Only 3 Ways To Increase Your IGF-1 (How To Pick The Right One)

Your pituitary gland makes growth hormone, your liver converts that growth hormone into something called IGF-1, which is insulin-like growth factor 1, and IGF-1 is what actually does the work: building muscle, burning fat, supporting recovery. That's the whole chain. And every compound marketed in the GH space, whether it's a peptide or pharmaceutical HGH or IGF-1 itself, is just targeting a different link in that chain.

Once you see where each one enters the system, the comparison stops being confusing.

The first category is GHRH analogs, which stands for growth hormone-releasing hormone analogs, meaning compounds that mimic the natural signal your hypothalamus sends to your pituitary to release GH. Tesamorelin, CJC-1295, and Sermorelin all work this way. You inject the signal, the pituitary responds by releasing your own stored GH, that GH travels to the liver, and your liver produces IGF-1. The whole endocrine axis stays intact.

The reason this matters is that the feedback loop stays intact too.

Your body runs GH on what functions like a thermostat. When IGF-1 rises high enough, the hypothalamus releases something called somatostatin, which is a braking signal that tells the pituitary to stop releasing GH. This is a hardwired ceiling. No matter how much GHRH analog you inject, you cannot push IGF-1 past the point where somatostatin kicks in and applies the brake. The system will not let you. This is not a flaw in the compounds. It is a physiological boundary built into the axis they work through.

That boundary is also why these compounds carry a lower risk profile and why they make sense for someone whose goal is restoring GH output to where it should naturally be, supporting sleep quality, body composition, and recovery without exceeding what the body's own regulatory system permits.

The second category is exogenous GH, meaning pharmaceutical human growth hormone injected directly. This enters the bloodstream and drives IGF-1 production at the liver without any signal from the pituitary. Because the signal is coming from outside the feedback loop, the loop cannot cap it the same way. Research from Rosenthal and colleagues showed that exogenous GH directly suppresses the pituitary's response to GHRH, which is the same mechanism that explains why adding a GHRH peptide on top of pharmaceutical HGH accomplishes almost nothing. The pituitary is already suppressed. The signal you're paying for has nowhere to land.

This is the stacking mistake people make most often, and it's expensive.

With exogenous GH, IGF-1 can be driven above the natural ceiling because the limiting step, pituitary output, has been bypassed entirely. Johannsson and colleagues found that GH treatment in abdominally obese men significantly reduced abdominal fat mass and improved both glucose and lipoprotein metabolism over six months of treatment. The tradeoff is that this requires ongoing use to sustain elevated IGF-1, and it requires regular bloodwork, because IGF-1 running too high carries its own risks that accumulate over time.

The third category skips the entire chain. IGF-1 LR3 is a synthetic, long-acting version of IGF-1 itself. You are not stimulating GH. You are not waiting for liver conversion. You are injecting the endpoint of the pathway directly into circulation. Chapman and colleagues demonstrated that exogenous IGF-1 suppresses GH release through feedback on the pituitary and hypothalamus, which means running IGF-1 LR3 shuts down your own GH axis while you're using it, and also means stacking it on top of anything else in the chain creates redundant signals competing at the same receptors.

Those receptors become the limiting factor with IGF-1 LR3.

Something called receptor desensitization happens when IGF-1 receptors are chronically exposed to elevated ligand, meaning the receptors downregulate and the same dose produces a weaker response over time. This is why IGF-1 LR3 has to be cycled at six to eight weeks maximum. Running it longer does not produce more effect. It produces tolerance and a suppressed axis with diminishing returns. This compound makes sense for a specific short-term goal with close monitoring. It is not a long-term tool.

Now there is a persistent belief that Tesamorelin is uniquely effective at burning visceral fat in a way that other GH compounds are not. What is true is that the clinical trials for Tesamorelin specifically measured visceral fat as the primary endpoint. Falutz and colleagues found that Tesamorelin reduced visceral fat area by approximately 15 percent compared to placebo in HIV patients with lipodystrophy, and Stanley and Grinspoon confirmed these metabolic effects in subsequent analysis. But the mechanism is not unique to Tesamorelin. It is GH-mediated lipolysis, which is the process by which growth hormone activates fat breakdown, and Moller and Jorgensen's review of GH metabolism makes clear that this is a property of GH itself, not of any specific compound that stimulates it.

Visceral fat has a higher density of GH receptors than subcutaneous fat, so when GH rises, visceral fat responds first and most. That is true whether the GH comes from Tesamorelin, Sermorelin, CJC-1295, or pharmaceutical HGH. Tesamorelin gets associated with visceral fat because that is what its trials were designed to measure, not because it does something the others cannot.

And none of it produces meaningful fat loss in a caloric surplus. GH-mediated lipolysis releases fatty acids from storage, but if energy intake exceeds expenditure, those fatty acids get repackaged. The compound does not override the energy balance equation.

So the decision framework simplifies to this. If your goal is restoring GH output within physiological limits, a GHRH analog does that at lower cost and lower risk. If your goal is sustained IGF-1 above your natural ceiling, pharmaceutical GH is the appropriate tool, but it requires bloodwork and ongoing use to do it safely. If you have a specific short-term goal and are willing to monitor closely, IGF-1 LR3 gets there fastest but cannot be run long-term without receptor desensitization undermining the whole point.

What most people are actually doing is stacking compounds across categories without understanding that each one is entering the same chain at a different point, and adding a second entry point does not double the output. It either creates redundant signals the body ignores, or it accelerates suppression of the parts of the axis you were trying to support.

The chain has three links. You are choosing which one to pull on.

---

References

1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357(23):2359-70. DOI: 10.1056/NEJMoa072375
2. Stanley TL, Grinspoon SK. (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 25(2):59-65. DOI: 10.1016/j.ghir.2014.12.005
3. Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. DOI: 10.1210/er.2008-0027
4. Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. J Clin Endocrinol Metab 85(2):601-6. DOI: 10.1210/jcem.85.2.6377
5. Rosenthal SM, Hulse JA, Kaplan SL, Grumbach MM. (1986). Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men. J Clin Invest 77(1):176-83. DOI: 10.1172/JCI112273
6. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO. (1998). Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I: evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83(8):2836-42. DOI: 10.1210/jcem.83.8.5040
7. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82(3):727-34. DOI: 10.1210/jcem.82.3.3809

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness